What problem does this paper attempt to address?

The problem that this paper attempts to solve is to determine the relationship between the use of tranexamic acid (TXA) in patients with different trauma phenotypes and in - hospital mortality. Specifically, the study aims to evaluate the impact of TXA administration on in - hospital mortality in patients with blunt trauma by analyzing the Japanese national trauma registry data, and to explore this association based on clinical phenotypes. ### Research Background Despite global efforts in standardizing trauma care and improving treatment outcomes, approximately 4.5 million people still die from trauma each year. Early preventable trauma deaths are mainly caused by bleeding, and trauma - induced coagulopathy (TIC) can exacerbate acute bleeding, leading to shock, ischemia - reperfusion injury, thrombus complications, and, in severe cases, hyperfibrinolysis, further promoting bleeding. TXA, as an antifibrinolytic drug, functions by inhibiting the lysine - binding sites on plasminogen. International randomized controlled trials (such as CRASH - 2 and CRASH - 3) have shown that TXA has a potential improvement effect in patients with traumatic bleeding and mild - to - moderate traumatic brain injury. Therefore, early management of bleeding and coagulation abnormalities in trauma is recommended as part of trauma care. ### Research Objectives This study used data from the Japan Trauma Data Bank (JTDB) to evaluate the relationship between TXA administration and in - hospital mortality based on clinical phenotypes. The study hypothesized that different trauma phenotypes would lead to heterogeneity in the treatment effect of TXA. By determining which trauma phenotype patients may benefit or be harmed from TXA treatment, it can assist clinical decision - making and fill the knowledge gap regarding the optimal TXA administration strategy. ### Main Findings - **Beneficial Phenotypes**: Trauma phenotypes 1, 2, 6, and 8 had a significant reduction in in - hospital mortality after receiving TXA treatment (ORs were 0.68, 0.73, 0.52, and 0.67 respectively). - **Adverse Phenotypes**: Trauma phenotypes 3 and 4 had a significant increase in in - hospital mortality after receiving TXA treatment (ORs were 2.62 and 1.39 respectively). ### Conclusions This is the first study to evaluate the relationship between TXA administration and survival outcomes based on clinical phenotypes. The study found that there is an association between trauma phenotypes and in - hospital mortality, indicating that TXA treatment may have an impact on this relationship. Future research is needed to further evaluate the practicality of these phenotypes. ### Method Overview - **Data Source**: Data from the Japan Trauma Data Bank (JTDB) from 2019 to 2021. - **Sample Selection**: A total of 53,703 patients with blunt trauma were included, of which 8,046 (15.0%) received TXA treatment. - **Statistical Method**: Inverse probability treatment weighting (IPTW) was used to adjust for confounding factors, and the odds ratio (OR) of TXA administration and in - hospital mortality in each trauma phenotype was calculated through a logistic regression model. ### Significance This study provides important information for clinicians, helping them more precisely decide whether to use TXA in patients with specific trauma phenotypes, thereby optimizing treatment outcomes.

Association between tranexamic acid administration and mortality based on the trauma phenotype: a retrospective analysis of a nationwide trauma registry in Japan

Tranexamic Acid in Pediatric Traumatic Brain Injury: A Multicenter Retrospective Observational Study

The Short- and Long-Term Risk of Mortality in Intracranial Hemorrhage Patients with Tranexamic Acid Treatment in a Population-Based Cohort Study

Efficacy and Safety of Tranexamic Acid in Emergency Trauma: A Systematic Review and Meta-Analysis

Intraoperative Tranexamic Acid is Associated with Postoperative Stroke in Patients Undergoing Cardiac Surgery

Does tranexamic acid increase venous thromboembolism risk among trauma patients? A prospective multicenter analysis across 17 level I trauma centers

Factors that influence the administration of tranexamic acid (TXA) to trauma patients in prehospital settings: a systematic review

Does tranexamic acid have a positive effect on the outcome of older multiple trauma patients on antithrombotic drugs? An analysis using the TraumaRegister DGU®

Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single‐Blind Randomized Controlled Trial

Tranexamic Acid is Not Associated With a Change in Infection Risk in Trauma Patients

Research Priorities in Tranexamic Acid After Trauma: Secondary Analysis of the National Trauma Research Action Plan

Thromboembolic Complications Following Perioperative Tranexamic Acid Administration

Population pharmacokinetic modelling and simulation of tranexamic acid in adult trauma patients

Safety assessment of tranexamic acid: real-world adverse event analysis from the FAERS database

Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients

Prehospital tranexamic acid is associated with a survival benefit without an increase in complications: results of two harmonized randomized clinical trials

Effectiveness of Tranexamic Acid in Trauma Patients: A Systematic Review

Developing a simple field triage scheme compatible with regional trauma situations and medical systems using machine learning: A nationwide trauma database study

Trauma‐targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model

The effects of prehospital TXA on mortality and neurologic outcomes in patients with traumatic intracranial hemorrhage: a subgroup analysis from the prehospital TXA for TBI trial

Retrospective analysis of tranexamic acid administration in French war-wounded between October 2016 and September 2020